An­oth­er biotech start­up runs in­to a PhII pile­up in Parkin­son's

GLP-1R ag­o­nists have be­come stan­dard ther­a­pies in di­a­betes, with some proven weight loss fea­tures and a safe­ty pro­file that promis­es to bring them in­to the main­stream as obe­si­ty drugs. But when Seul­ki Lee was at Johns Hop­kins for a lengthy stretch as an as­so­ciate pro­fes­sor, he and the not­ed neu­ro­sci­en­tist Ted Daw­son spent time in­ves­ti­gat­ing the an­ti-in­flam­ma­to­ry side of the drug that they felt had re­al po­ten­tial in treat­ing neu­rode­gen­er­a­tive dis­eases like Alzheimer’s and Parkin­son’s.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER